Novel NF-κB inhibitors: a patent review (2011 – 2014). (March 2015)

• Record Type: Journal Article
• Authors: Arepalli, Sateesh Kumar; Choi, Minho; Jung, Jae-Kyung; Lee, Heesoon
• Is Part Of: Expert opinion on therapeutic patents. Volume 25:Number 3(2015:Mar.)
• Page Start: 319
• Page End: 334
• Publication Date: 2015-03
• Subjects: Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1517/13543776.2014.998199
• Languages: English
• ISSNs: 1354-3776

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Importance of the field:</italic> </bold> The NF-κB family of transcription factors has a vital role in coordinating the expression of a wide variety of genes that control immune responses. The dysfunction of NF-κB has been associated with diseases ranging from inflammation to cancer.</p> <p> <bold> <italic>Areas covered:</italic> </bold> In this review, authors provided information on the role of NF-κB in human health and on recently developed inhibitors from patents granted in 2011 – 2014. The reader will gain an understanding of the mechanisms of NF-κB function as well as the structures and biological activities of recently developed NF-κB inhibitors.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> Constitutive NF-κB activation is likely involved in the pathogenesis of several diseases. Researchers need to consider the specific mechanism of each invented NF-κB inhibitor, as well as the properties of the cellular, <italic>in vitro</italic> and <italic>in vivo</italic> assays and targeted diseases. For new drug development, they need various biological tests to assess the potential side effects and optimization of the biological activity.</p> </abstract>